Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06286033 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study and Food Effect Study for AG181
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 88
- Enrollment target
NCT06286033: Completed Phase 1 study, sponsored by Agios Pharmaceuticals.
NCT06286033 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 88 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06286033, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single oral doses of AG-181 in healthy participants in Part 3.
Interventions
- DRUG Placebo
- DRUG AG-181
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2024-02-20 |
| Est. Completion | 2025-10-09 |
| Phase | Phase 1 |
What the finished NCT06286033 record still lists
NCT06286033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06286033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06286033 about?
NCT06286033 is a clinical study titled "Single and Multiple Ascending Dose Study and Food Effect Study for AG181". The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single o...
What is the current status of trial NCT06286033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 88 participants. The study started on 2024-02-20. Estimated completion is 2025-10-09.
What interventions are being tested in trial NCT06286033?
The interventions under investigation include: Placebo (DRUG), AG-181 (DRUG).
Who is sponsoring clinical trial NCT06286033?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06286033's enrollment target sits among peer trials
88 650th of 2000 higher than 1,350 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI